<DOC>
	<DOCNO>NCT00907166</DOCNO>
	<brief_summary>The objective study : - To determine safety MTD CPI-613 , use combination Gemcitabine , cancer patient . - To compare safety efficacy CPI-613/Gemcitabine combination vs. Gemcitabine alone patient carcinoma pancreas .</brief_summary>
	<brief_title>A Phase I/II Open-Label Dose-Escalation Clinical Trial CPI-613 Combination With Gemcitabine Cancer Patients</brief_title>
	<detailed_description>CPI-613 , investigational drug , novel anti-tumor compound believe operate via novel mechanism action belong exist pharmacological class anticancer agent currently use clinic . Specifically , CPI-613 Cornerstone Pharmaceutical Inc. 's lead drug Altered Energy Metabolism-Directed ( AEMD ) technology platform . It selective tumor cell ( normal cell ) accord preclinical study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>For Stages 1 2 study , histologically document unresectable primary metastatic carcinoma pancreas , Stage IIIV , diagnose within past 8 week , intend treated Gemcitabine single agent 1000 mg/m^2 weekly 3 week repeat cycle every 4 week . For Stage 1 Stage 2 study , patient also include histologically document unresectable primary metastatic carcinoma pancreatic carcinoma ( e.g. , bladder cancer , NSCLC , biliary tract cancer ) intend treat Gemcitabine single agent 1000 mg/m^2 weekly 3 week repeat cycle every 4 week , regardless Gemcitabine use second , third fourth line treatment . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Expected survival &gt; 2 month . 1870 year age gender Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must use accepted contraceptive method ( abstinence , intrauterine device [ IUD ] , oral contraceptive double barrier device ) study , must negative serum urine pregnancy test within 1 week prior treatment initiation . Fertile men must practice effective contraceptive method study , unless documentation infertility exist . No radiotherapy , treatment cytotoxic agent chemotherapeutic agent ( except CPI613 ) , treatment biologic agent within 2 week prior treatment CPI613 . At least 2 week must elapse prior surgery hormonal therapy . Patients must fully recover acute toxicity prior treatment cytotoxic drug , radiotherapy anticancer modality ( return baseline status note recent treatment ) . Patients persist , stable chronic toxicity prior treatment ≤Grade 1 eligible , must document . Laboratory value ≤2 week must : Adequate hematologic ( white blood cell [ WBC ] ≥3500 cells/mm^3 ≥3.5 bil/L ; platelet count ≥150,000 cells/mm^3 ≥150 bil/L ; absolute neutrophil count [ ANC ] ≥1500 cells/mm3 ≥1.5 bil/L ; hemoglobin ≥9 g/dL ≥90 g/L ) . Adequate hepatic function ( aspartate aminotransferase [ AST/SGOT ] ≤3x upper normal limit [ UNL ] , alanine aminotransferase [ ALT/SGPT ] ≤3x UNL ( ≤5x UNL liver metastasis present ) , bilirubin ≤3x UNL ) . Adequate renal function ( serum creatinine ≤2.0 mg/dL 177 µmol/L ) . Adequate coagulation ( International Normalized Ratio INR must be≤1.5 ) No evidence active infection serious infection within past month . Mentally competent , ability understand willingness sign inform consent form . Prior therapy Gemcitabine Serious medical illness , significant cardiac disease ( e.g . symptomatic congestive heart failure , unstable angina pectoris , myocardial infarction within past 6 month , uncontrolled cardiac arrhythmia , New York Heart Association Class III IV ) , severe debilitate pulmonary disease , would potentially increase patient ' risk toxicity . Patients active central nervous system ( CNS ) epidural tumor . Any active uncontrolled bleeding , patient bleed diathesis ( e.g. , active peptic ulcer disease ) . Pregnant woman , woman childbearing potential use reliable mean contraception ( teratogenic potential CPI613 unknown ) . Lactating female . Fertile men unwilling practice contraceptive method study period . Life expectancy le 2 month . Any condition abnormality may , opinion investigator , compromise safety patient . Unwilling unable follow protocol requirement . Dyspnea minimal moderate exertion . Patients large pleural , pericardial , peritoneal effusion . Active heart disease include myocardial infarction within previous 6 month , symptomatic coronary artery disease , arrhythmias require medication , symptomatic congestive heart failure . Albumin &lt; 2.5 g/dL &lt; 25 g/L . Evidence active infection , serious infection within past month . Patients know HIV infection . Patients receive standard investigational treatment cancer , investigational agent indication within past 4 week prior initiation CPI613 treatment . Patients receive immunotherapy type within past 4 week prior initiation CPI613 treatment . Requirement immediate palliative treatment kind include surgery . Patients receive chemotherapy regimen stem cell support previous 6 month . A marked baseline prolongation QT/QTc interval ( e.g. , repeat exhibition QTc interval &gt; 470 ms. ) A history additional risk factor torsade de pointes ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) Prior illicit drug addiction . Any condition abnormality may , opinion investigator , compromise safety patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cornerstone Pharmaceuticals , Inc .</keyword>
	<keyword>CPI-613</keyword>
	<keyword>Altered Energy Metabolism Directed Compound</keyword>
	<keyword>Phase I</keyword>
	<keyword>Phase II</keyword>
	<keyword>Cancer</keyword>
	<keyword>Carcinoma Pancreas</keyword>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Pancreatic Carcinoma</keyword>
</DOC>